U2Bio Statistics

Total Valuation

U2Bio has a market cap or net worth of KRW 35.27 billion. The enterprise value is 1.41 billion.

Market Cap	35.27B
Enterprise Value	1.41B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

U2Bio has 11.29 million shares outstanding. The number of shares has increased by 6.54% in one year.

Current Share Class	11.29M
Shares Outstanding	11.29M
Shares Change (YoY)	+6.54%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	18.64%
Owned by Institutions (%)	0.00%
Float	5.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.41
PB Ratio	1.03
P/TBV Ratio	1.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.51
EV / Sales	0.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.07

Financial Position

The company has a current ratio of 6.87, with a Debt / Equity ratio of 0.01.

Current Ratio	6.87
Quick Ratio	6.68
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.55
Interest Coverage	-66.03

Financial Efficiency

Return on equity (ROE) is -7.70% and return on invested capital (ROIC) is -4.84%.

Return on Equity (ROE)	-7.70%
Return on Assets (ROA)	-3.81%
Return on Invested Capital (ROIC)	-4.84%
Return on Capital Employed (ROCE)	-7.29%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.55
Inventory Turnover	25.52

Taxes

In the past 12 months, U2Bio has paid 1.22 billion in taxes.

Income Tax	1.22B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.33% in the last 52 weeks. The beta is -0.21, so U2Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.21
52-Week Price Change	-25.33%
50-Day Moving Average	3,103.00
200-Day Moving Average	3,075.45
Relative Strength Index (RSI)	52.88
Average Volume (20 Days)	32,096

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, U2Bio had revenue of KRW 25.08 billion and -2.75 billion in losses. Loss per share was -244.04.

Revenue	25.08B
Gross Profit	4.87B
Operating Income	-2.79B
Pretax Income	-1.53B
Net Income	-2.75B
EBITDA	-1.93B
EBIT	-2.79B
Loss Per Share	-244.04

Full Income Statement

Balance Sheet

The company has 34.24 billion in cash and 371.23 million in debt, giving a net cash position of 33.87 billion or 3,000.39 per share.

Cash & Cash Equivalents	34.24B
Total Debt	371.23M
Net Cash	33.87B
Net Cash Per Share	3,000.39
Equity (Book Value)	34.10B
Book Value Per Share	3,020.90
Working Capital	35.67B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -666.60 million and capital expenditures -12.52 million, giving a free cash flow of -679.11 million.

Operating Cash Flow	-666.60M
Capital Expenditures	-12.52M
Free Cash Flow	-679.11M
FCF Per Share	-60.17

Full Cash Flow Statement

Margins

Gross margin is 19.41%, with operating and profit margins of -11.13% and -10.95%.

Gross Margin	19.41%
Operating Margin	-11.13%
Pretax Margin	-6.08%
Profit Margin	-10.95%
EBITDA Margin	-7.71%
EBIT Margin	-11.13%
FCF Margin	n/a

Dividends & Yields

U2Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.54%
Shareholder Yield	-6.54%
Earnings Yield	-7.79%
FCF Yield	-1.93%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 23, 2023. It was a forward split with a ratio of 4.

Last Split Date	Feb 23, 2023
Split Type	Forward
Split Ratio	4

Scores

U2Bio has an Altman Z-Score of 4.06 and a Piotroski F-Score of 2.

Altman Z-Score	4.06
Piotroski F-Score	2